TY - JOUR
T1 - Evolution in Endometrial Cancer Evidence From an Immunohistochemical Study
AU - Vandenput, Ingrid
AU - Trovik, Jone
AU - Leunen, Karin
AU - Wik, Elisabeth
AU - Stefansson, Ingunn
AU - Akslen, Lars
AU - Moerman, Philippe
AU - Vergote, Ignace
AU - Salvesen, Helga
AU - Amant, Frédéric
PY - 2011
Y1 - 2011
N2 - Background: It is poorly described how endometrial cancer biology changes during tumor evolution. We hypothesize that characterization of molecular targets in recurrent lesions is more relevant for targeting treatment. Methods: Paired biopsies from primary and recurrent endometrial cancer tumors (n = 85) were stained immunohistochemically for the following proteins: estrogen receptor (ER), progesterone receptor (PR), stathmin (correlating with phosphatidylinositol 3-kinase activity), HER-2/neu, WT1 (Wilms tumor gene 1), phospho-mammalian target of rapamycin (p-mTOR), and p53. Each tumor was scored, using a semiquantitative and subjective grading system. Discordance, a change in expression between primary and recurrent tumor, was defined as >= 2 step change; concordance was <= 1 step change. The frequency of change was correlated with established prognostic markers in endometrial cancer. Results: Fifty-six patients (67%) were diagnosed with endometrioid carcinoma, 23 (27%) with serous/clear cell carcinoma. A change in expression between primary and recurrent tumor was noted in 7% to 31% of patients for ER, PR, stathmin, HER-2/neu, WT1, p-mTOR, and p53. Concordant-positive cases for PR were significantly correlated with stage, tumor grade, and histological subtype. Expression of ER, p53, and p-mTOR in cytoplasm in the recurrent tumor correlated significantly with survival. Conclusions: Endometrial cancer biology changes over time. The decision on targeted treatment should preferably be based on recurrent tumor characteristics
AB - Background: It is poorly described how endometrial cancer biology changes during tumor evolution. We hypothesize that characterization of molecular targets in recurrent lesions is more relevant for targeting treatment. Methods: Paired biopsies from primary and recurrent endometrial cancer tumors (n = 85) were stained immunohistochemically for the following proteins: estrogen receptor (ER), progesterone receptor (PR), stathmin (correlating with phosphatidylinositol 3-kinase activity), HER-2/neu, WT1 (Wilms tumor gene 1), phospho-mammalian target of rapamycin (p-mTOR), and p53. Each tumor was scored, using a semiquantitative and subjective grading system. Discordance, a change in expression between primary and recurrent tumor, was defined as >= 2 step change; concordance was <= 1 step change. The frequency of change was correlated with established prognostic markers in endometrial cancer. Results: Fifty-six patients (67%) were diagnosed with endometrioid carcinoma, 23 (27%) with serous/clear cell carcinoma. A change in expression between primary and recurrent tumor was noted in 7% to 31% of patients for ER, PR, stathmin, HER-2/neu, WT1, p-mTOR, and p53. Concordant-positive cases for PR were significantly correlated with stage, tumor grade, and histological subtype. Expression of ER, p53, and p-mTOR in cytoplasm in the recurrent tumor correlated significantly with survival. Conclusions: Endometrial cancer biology changes over time. The decision on targeted treatment should preferably be based on recurrent tumor characteristics
U2 - https://doi.org/10.1097/IGC.0b013e31820575f5
DO - https://doi.org/10.1097/IGC.0b013e31820575f5
M3 - Article
C2 - 21734474
SN - 1048-891X
VL - 21
SP - 316
EP - 322
JO - International journal of gynecological cancer
JF - International journal of gynecological cancer
IS - 2
ER -